ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the Jefferies Global Healthcare Conference, being held June 3-5, 2025. During the event, I-Mab's management will discuss clinical progress on its lead program, givastomig. I-Mab also recently announced that new data on givastomig ...

金十图示：2025年05月16日（周五）热门中概股行情一览（美股盘中） 149.53亿市值 92.06亿市值 79.59亿市值 107.40 4.07 48.67 +1.64(+1.55%) +0.07(+1.88%) -0.16(-0.33%) 降層降暖 TALHAR 好未来 唯品会 的比较 77.44亿市值 79.33亿市值 63.55亿市值 18.98 15.04 10.49 +1.24(+6.99%) +0.54(+3.72%) +0.34(+3.30%) 金山区 So 名创优品 C ) 奇富科技 63.27亿市值 61.78亿市值 37.20亿市值 20.23 44.03 13.53 -0.55(-2.62%) -0.18(-0.41%) +0.25(+1.88%) 再鼎医药 陆金所控股 asza 汽车之家 zal-ab the may 26.09亿市值 32.74亿市值 30.39亿市值 30.18 25.66 3.01 +1.44(+4.99%) -0.09(-0.35%) +0.09(+3.08%) 雾芯科技 tom 爱奇艺 RELX 21.22亿市值 18.30亿市值 24.31亿市值 1. ...

ROCKVILLE, Md., May 15, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the three months ended March 31, 2025, and highlighted recent pipeline progress and business updates. "2025 is off to a strong start for I-Mab. Designation of givastomig as our lead program has enabled us to unlock significant value for the Company by consi ...

市值与股价变动 - 名创优品市值为74.11亿，股价下跌0.95(-1.99%) [2] - 唯品会市值为88.55亿，股价上涨0.15(+0.85%) [2] - 可富科技市值为76.47亿，股价上涨0.07(+1.83%) [2] - 好未来市值为55.44亿，股价下跌0.04(-0.49%) [2] - 再鼎医药市值为31.49亿，股价上涨0.96(+3.75%) [2] - 陆金所控股市值为31.04亿，股价下跌0.23(-0.79%) [2] - 微博市值为23.49亿，股价上涨0.08(+0.95%) [2] - 爱奇艺市值为22.36亿，股价下跌0.05(-1.81%) [2] - 乐信市值为18.49亿，股价上涨0.03(+1.59%) [2] - 老虎证券市值为16.28亿，股价上涨0.08(+0.87%) [2] - 网易有道市值为13.93亿，股价上涨0.16(+1.97%) [2] - 优信市值为9.24亿，股价下跌0.03(-0.34%) [2] - 虎牙市值为9.59亿，股价上涨0.01(+0.22%) [2] - 诺亚控股市值为8.06亿，股价下跌0.03(-0.77%) [2] - 高途市值为8.26亿，股价无变动 [2] - 达达市值为6.28亿，股价上涨0.01(+0.41%) [2] - 趣店市值为5.42亿，股价无变动 [2] - 小牛电动市值为4.87亿，股价上涨0.02(+0.68%) [2] - 逸仙电商市值为3.27亿，股价无变动 [2] - 搜狐市值为3.95亿 [2] - 迅雷市值为2.73亿，股价上涨0.07(+1.62%) [3] - 宝尊电商市值为2.02亿，股价上涨0.17(+5.18%) [3] - 第九城市市值为1.53亿，股价上涨0.27(+2.54%) [3] - 途牛市值为1.08亿，股价下跌0.01(-1.20%) [3] - 新氧市值为8307.17万，股价无变动 [3] - 天境生物市值为7431.09万，股价上涨0.02(+2.25%) [3] - 华米科技市值为3763.14万，股价上涨0.09(+3.52%) [3] - 房多多市值为1115.43万，股价无变动 [3] - 易电行市值为220.99万，股价无变动 [3] 财务数据 - 名创优品财务数据为3.91 [2] - 唯品会财务数据为46.76 [2] - 可富科技财务数据为17.73 [2] - 好未来财务数据为9.15 [2] - 再鼎医药财务数据为26.59 [2] - 陆金所控股财务数据为28.14 [2] - 微博财务数据为2.71 [2] - 爱奇艺财务数据为1.83 [2] - 乐信财务数据为1.92 [2] - 老虎证券财务数据为8.28 [2] - 网易有道财务数据为9.25 [2] - 优信财务数据为5.97 [2] - 虎牙财务数据为8.82 [2] - 诺亚控股财务数据为3.69 [2] - 高途财务数据为3.23 [2] - 达达财务数据为9.47 [2] - 趣店财务数据为2.95 [2] - 小牛电动财务数据为6.27 [2] - 逸仙电商财务数据为4.30 [2] - 搜狐财务数据为10.87 [2] - 迅雷财务数据为4.38 [3] - 宝尊电商财务数据为3.45 [3] - 第九城市财务数据为10.88 [3] - 途牛财务数据为0.93 [3] - 新氧财务数据为0.82 [3] - 天境生物财务数据为0.91 [3] - 华米科技财务数据为2.62 [3] - 房多多财务数据为0.23 [3] - 易电行财务数据为0.39 [3]

市值数据 - 荷富科技市值142.97亿，唯品会市值88.89亿，Libb市值79.83亿 [2] - 好未来市值55.74亿，金山云市值58.37亿，名创优品市值42.40亿 [2] - 再鼎医药市值25.00亿，陆金所控股市值33.05亿，汽车之家市值32.09亿 [2] - 雾芯科技市值19.26亿，爱奇艺市值21.75亿，微博市值22.54亿 [2] - 乐信市值14.52亿，老虎证券市值16.46亿，优信市值10.74亿 [2] - 高途市值9.92亿，虎牙市值8.56亿，诺亚财富市值9.82亿 [2] - 达达市值8.42亿，逸仙电商市值6.33亿，趣店市值5.46亿 [2] - 搜狐市值3.60亿，小牛电动市值2.86亿，金融壹账通市值2.81亿 [3] - 斗鱼市值2.42亿，宝尊电商市值2.32亿，第九城市市值1.78亿 [3] - 猎豹移动市值1.48亿，途牛市值1.21亿，云米市值1.11亿 [3] - 天境生物市值9821.91万，新氧市值8407.86万，华米科技市值7275.94万 [3] - 蘑菇街市值3663.86万，极光市值1840.39万，开心汽车市值5310.61万 [3] - 房多多市值1648.27万，易电行市值974.85万 [3] 股价变动 - 唯品会股价-1.10(-2.20%)，Libb股价+1.52(+1.50%)，荷富科技股价-0.06(-1.38%) [2] - 好未来股价+0.13(+0.70%)，金山云股价+0.15(+1.71%)，名创优品股价-0.48(-3.02%) [2] - 再鼎医药股价-0.07(-2.53%)，陆金所控股股价-0.99(-3.21%)，汽车之家股价+0.23(+0.86%) [2] - 雾芯科技股价-0.01(-0.54%)，爱奇艺股价+0.22(+2.60%)，微博股价+0.04(+2.04%) [2] - 乐信股价+0.38(+4.26%)，老虎证券股价+0.37(+4.47%)，优信股价+0.22(+2.51%) [2] - 高途股价+0.23(+3.91%)，虎牙股价-0.38(-7.32%)，诺亚财富股价+0.01(+0.44%) [2] - 达达股价-0.01(-0.24%)，逸仙电商股价-0.04(-1.18%)，趣店股价+0.10(+1.06%) [2] - 搜狐股价+0.01(+0.51%)，小牛电动股价+0.14(+4.80%)，金融壹账通股价0.00(0.00%) [3] - 斗鱼股价+0.10(+1.64%)，宝尊电商股价+0.08(+1.05%)，第九城市股价+0.18(+6.32%) [3] - 猎豹移动股价-0.58(-5.21%)，途牛股价+0.05(+5.24%)，云米股价+0.18(+4.80%) [3] - 天境生物股价+0.01(+0.98%)，新氧股价0.00(-0.01%)，华米科技股价+0.04(+4.21%) [3] - 蘑菇街股价0.00(0.00%)，极光股价+0.30(+3.55%)，开心汽车股价-0.11(-4.14%) [3] - 房多多股价-0.05(-3.45%)，易电行股价-0.01(-2.23%) [3] 其他数据 - 唯品会数据102.69，Libb数据3.92，荷富科技数据48.82 [2] - 好未来数据15.42，金山云数据18.66，名创优品数据9.21 [2] - 再鼎医药数据29.95，陆金所控股数据2.88，汽车之家数据27.09 [2] - 雾芯科技数据1.85，爱奇艺数据2.00，微博数据8.69 [2] - 乐信数据9.35，老虎证券数据8.98，优信数据8.63 [2] - 高途数据4.81，虎牙数据3.42，诺亚财富数据6.11 [2] - 达达数据3.77，逸仙电商数据9.53，趣店数据6.32 [2] - 搜狐数据11.97，小牛电动数据4.50，金融壹账通数据3.67 [3] - 斗鱼数据6.20，宝尊电商数据7.70，第九城市数据3.03 [3] - 猎豹移动数据10.56，途牛数据3.93，云米数据0.96 [3] - 天境生物数据0.89，新氧数据1.44，华米科技数据0.83 [3] - 蘑菇街数据8.74，极光数据2.24，开心汽车数据2.55 [3] - 房多多数据0.23，易电行数据0.39 [3]

文章核心观点 - 公司宣布givastomig联合疗法研究摘要被2025年ESMO胃肠道癌症大会接受进行小型口头报告 [1] 会议信息 - ESMO胃肠道癌症大会将于7月2 - 5日在西班牙巴塞罗那举行 [1] 公司表态 - 公司首席医学官对givastomig新临床数据被接受为口头报告表示高兴，期待会议提供更多信息 [2] Givastomig介绍 - Givastomig是靶向Claudin 18.2阳性肿瘤细胞的双特异性抗体，通过4 - 1BB信号通路激活T细胞，用于一线转移性胃癌，在其他实体瘤也有潜力 [3] - 1期试验中givastomig显示出有前景的抗肿瘤活性，同时降低其他4 - 1BB药物常见毒性 [3] 研究进展 - 1b期研究评估givastomig联合标准治疗、nivolumab和化疗治疗一线胃癌，剂量递增已完成，首个剂量扩展队列提前完成入组，第二个剂量扩展队列入组进展顺利 [4] 合作情况 - Givastomig由公司与ABL Bio全球合作开发，公司为牵头方，与ABL Bio平分除大中华区和韩国外的全球权利 [5] 公司概况 - 公司是美国的全球生物技术公司，专注开发精准免疫肿瘤药物治疗癌症，在美国马里兰州罗克维尔和新泽西州肖特山开展业务 [6] 投资者与媒体联系方式 - PJ Kelleher，LifeSci Advisors，电话+1 - 617 - 430 - 7579，邮箱pkelleher@lifesciadvisors.com和IR@imabbio.com [9]

2024年，中国创新药BD交易市场格外火热。根据研究报告显示，2024年我国药企共完成94笔license-out交易，总交易金额高达519亿美元，同比增长 26%；其中首付款41亿美元，同比上涨16%。 图1.2018-2024年中国药企licence-out交易数量及首付款（数据来源：医药魔方） 进入2025年，这一势头仍在延续。据悉，在刚刚过去的第一季度，就已经出现了超20笔涉及中国药企全球授权的交易，这其中就包括罗氏豪掷超10亿美元 淘金信达生物，以及乐普生物就一款临床前ADC与ArriVent达成一笔超12亿美元的重磅合作。事实上，这还只是序幕，在专利悬崖的压力下，海外大药企 当前对于中国创新药空前热情，并计划进一步"扫货"。这意味着，BD交易有望在今年再创新高。 而在一片热闹之中，不少国内药企已经尝到了甜头。比如映恩生物，其成立仅六年license-out就已卖出超60亿美元，这推动其在近期成功登陆港交所，并 以113%的涨幅创下18A企业历史最高纪录。另外吃到BD红利的还有百利天恒，2024年其不仅实现了扭亏为盈，并且净利大幅增长575%来到37.08亿元，而 这离不开一笔史诗级BD——2023 ...

I-Mab Sponsored ADR (IMAB) has been beaten down lately with too much selling pressure. While the stock has lost 20.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillat ...

I-Mab Sponsored ADR (IMAB) has been beaten down lately with too much selling pressure. While the stock has lost 19.7% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscil ...

Exhibit 99.1 I-Mab Reports Full Year 2024 Financial Results and Provides Business Update ROCKVILLE, MD, April 3, 2025 – I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the full year ended December 31, 2024, and highlighted recent pipeline progress and business updates. Givastomig is being jointly developed through a global partnership with ABL Bio, in ...